DATED 23 MARCH 2023Replimune Group, Inc. • May 18th, 2023 • Biological products, (no disgnostic substances)
PRESCRIBED CLAUSES LR1. Date of lease : 23 March 2023 LR2. Title number(s) LR2.1 Landlord’s title number(s)ON130606LR2.2 Other title number(s)BK102078, ON122118, ON122717, ON145942, ON146219, ON225380, ON38283, ON72772, ON96949, ON216090 LR3. Parties to this lease : LandlordMEPC MILTON PARK NO. 1 LIMITED (Company number 5491670) and MEPC MILTON PARK NO. 2 LIMITED (Company number 5491806), on behalf of MEPC Milton LP (LP No. LP14504), both of whose registered offices are at Sixth Floor, 150 Cheapside, London EC2V 6ET TenantREPLIMUNE LIMITED (Company number 09496393) whose registered office is at 69 Innovation Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RQOther partiesNone LR4. Property : In the case of a conflict between this clause and the remainder of this lease then, for the purposes of registration, this clause shall prevail.68GH Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RX shown edged red on the Plan with a net internal floor area of 191 s
REPLIMUNE GROUP, INC. RESTRICTED STOCK UNIT GRANT AGREEMENTReplimune Group, Inc. • May 18th, 2023 • Biological products, (no disgnostic substances) • Delaware
Pursuant to the terms of the Employment Agreement dated December 30, 2022 between Replimune, Inc. (the “Company”) and the Participant (as it may be amended from time to time, the “Employment Agreement”), the Company agreed to provide for the grant of restricted stock units to the Participant on the terms and subject to the conditions set forth herein. The Committee has decided to make this grant of restricted stock units as an inducement material for the Participant to enter into employment with the Company and to align the Participant’s interests with those of the Company and its stockholders. The grant of the restricted stock units provided for herein is intended to constitute an “employment inducement grant” as described in Rule 5635(c)(4), or any successor provision, of the Nasdaq Listing Rules, and is not being issued under the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan, as amended from time to time (the “Plan”). Capitalized terms used herein and not otherwise
REPLIMUNE GROUP, INC. NONQUALIFIED STOCK OPTION GRANT AGREEMENTEmployment Agreement • May 18th, 2023 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Delaware
Pursuant to the terms of the Employment Agreement dated December 30, 2022 between Replimune, Inc. (the “Company”) and the Participant (as it may be amended from time to time, the “Employment Agreement”), the Company agreed to provide for the grant of an option to acquire shares of Company common stock, $0.001 par value per share (“Company Stock”) to the Participant on the terms and subject to the conditions set forth herein. The Committee has decided to make this nonqualified stock option grant as an inducement material for the Participant to enter into employment with the Company and to align the Participant’s interests with those of the Company and its stockholders. The grant of the option provided for herein is intended to constitute an “employment inducement grant” as described in Rule 5635(c)(4), or any successor provision, of the Nasdaq Listing Rules, and is not being issued under the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan, as amended from time to time (th
